Results 21 to 30 of about 4,930 (158)

Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV [PDF]

, 2018
OBJECTIVE: To evaluate elvitegravir and cobicistat pharmacokinetics during pregnancy compared with postpartum and in infant washout samples after delivery.
Smith, Elizabeth, Burchett, Sandra, Wang, Jiajia, Badell, Martina L, Acosta, Edward P, Best, Brookie M, Barr, Emily, Purswani, Murli, Capparelli, Edmund V, Chakhtoura, Nahida, Stek, Alice, Mirochnick, Mark, Park, Kyunghun, Momper, Jeremiah D, Shapiro, David E   +14 more
core   +1 more source

Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting

Antiviral Therapy, 2023
Background Cohort studies suggest higher discontinuation rates with integrase strand transfer inhibitors (INSTIs) than are seen in clinical trials. We assessed discontinuations and adverse events (AEs) that were considered related to the initial INSTI in
Charlotte-Paige Rolle MD, MPH, Jamie Castano, Vu Nguyen MS, Kiran Patel, Federico Hinestrosa MD, Edwin DeJesus MD   +5 more
doaj   +1 more source

Inhibition of HTLV-1 Infection by HIV-1 First- and Second-Generation Integrase Strand Transfer Inhibitors

Frontiers in Microbiology, 2019
More than 10 million people worldwide are infected with the retrovirus human T-cell lymphotropic virus type 1 (HTLV-1). Infection phenotypes can range from asymptomatic to severe adult T-cell leukemia/lymphoma (ATLL) and HTLV-1-associated myelopathy ...
Michał S. Barski, Jordan J. Minnell, Goedele N. Maertens   +2 more
doaj   +1 more source

A microscopy-based small molecule screen in primary neurons reveals neuroprotective properties of the FDA-approved anti-viral drug Elvitegravir

Molecular Brain, 2020
Glutamate toxicity is a pathomechanism that contributes to neuronal cell death in a wide range of acute and chronic neurodegenerative and neuroinflammatory diseases.
Simon F. Merz, C. Peter Bengtson, Clara Tepohl, Anna M. Hagenston, Hilmar Bading, Carlos Bas-Orth   +5 more
doaj   +1 more source

Week 96 Results of Switching from Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide among HIV/Hepatitis B Virus-Coinfected Patients

Microbiology Spectrum, 2023
Data regarding the durability of tenofovir alafenamide (TAF)-containing antiretroviral therapy (ART) in maintaining hepatitis B virus (HBV) viral suppression among HIV/HBV-coinfected patients are limited.
Yu-Shan Huang, Chien-Yu Cheng, Hsin-Yun Sun, Shu-Hsing Cheng, Po-Liang Lu, Chen-Hsiang Lee, Yuan-Ti Lee, Hung-Chin Tsai, Chia-Jui Yang, Chun-Eng Liu, Bo-Huang Liou, Shih-Ping Lin, Sung-Hsi Huang, Mao-Wang Ho, Hung-Jen Tang, Chien-Ching Hung   +15 more
doaj   +1 more source

Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake [PDF]

, 2016
Objectives: To evaluate dolutegravir and elvitegravir/cobicistat pharmacokinetics in HIV-negative volunteers up to 10 days after drug cessation. Methods: Healthy volunteers received 50 mg of dolutegravir once-daily for 10 days, then underwent a 9 day ...
Owen, A, Else, L, Boffito, M, Amara, A, Elliot, E, Khoo, S, Moyle, G, Back, D, Jackson, A   +8 more
core   +1 more source

Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals [PDF]

, 2021
Objectives Co-formulated elvitegravir, cobicistat, tenofovir disoproxil fumarate and emtricitabine is among the preferred regimens for first-line ART. A population approach was used to characterize the pharmacokinetics of elvitegravir and cobicistat and ...
Decosterd, Laurent A., Keiser, O., Stöckle, M., Aouri, Manel, Martinez de Tejada, B., Hösli, I., Marzolini, C., Haerry, D., Battegay, M., Vernazza, P., Rudin, C., Kahlert, C., Böni, J., Kovari, H., Nadal, D., Weber, R., Kouyos, R., Regenass, S., Dollenmaier, G., Egger, M., Schmid, P., Günthard, H., Martinetti, G., Guidi, Monia, Bucher, HC, Hasse, B., Yerly, S., Braun, DL, Gaspar, Frédéric, Barceló, Catalina, Nicca, D., Burton-Jeangros, C., Buclin, Thierry, Bernasconi, E., Calmy, A., Trkola, A., Cavassini, M., Kaiser, L., Aubert, V., Elzi, L., Gorgievski, M., Hirsch, HH, Csajka, Chantal, Rotger, Margalida, Fellay, J., Panchaud, Alice, Müller, N., Rauch, A., Ledergerber, B., Tarr, P., Pantaleo, G., Metzner, K., Furrer, H., Hoffmann, M., Fux, CA, Speck, R., Klimkait, T., Fehr, J., Cavassini, Matthias, Schöni-Affolter, F.   +59 more
core  

Hepatic Steatosis Associated With Exposure to Elvitegravir and Raltegravir

, 2021
Moderate-to-severe hepatic steatosis in people living with human immunodeficiency virus (HIV) without viral hepatitis or excessive alcohol intake was associated with cumulative exposure to stavudine, elvitegravir, and raltegravir.
Gelpi, Marco, Thomsen, Magda Teresa, Kirkegaard-Klitbo, Ditte Marie, Nielsen, Susanne Dam, Benfield, Thomas, Bendtsen, Flemming   +5 more
core   +1 more source

HIV/HCV-coinfection: which role can new antiretrovirals such as integrase inhibitors play?

European Journal of Medical Research, 2009
End-stage liver disease has become one of the most frequent causes of death in HIV/HCV-coinfected patients. The role of new antiretrovirals in the progression of liver fibrosis has yet to be defined.
Vogel Martin, Nelson Mark
doaj   +1 more source

META-INSTI: metabolic adverse events following integrase strand transfer inhibitor administration in spontaneous adverse event reports

Drugs in Context, 2023
Background: Metabolic effects of integrase strand transfer inhibitors (INSTIs) have been reported. The FDA Adverse Event Reporting System (FAERS) is a publicly available database that captures spontaneously reported adverse events.
Milena M Murray, Lara Fakhouri, Spencer E Harpe   +2 more
doaj   +1 more source